A GLP-1 program can document what it sells without demonstrating how well its particular treatment performs. Sterling Private Medical illustrates that distinction. Its website presents a concierge telehealth practice with physician-directed care, discreet delivery and ongoing support. It also advertises three starting prices and identifies compounded medication as part of its offering. Those are useful service disclosures, but they are not clinical evidence that Sterling’s preparations produce the results seen in published drug trials.
This review examines Sterling’s public documentation consulted October 19, 2026, separating commercial promises, contractual responsibilities and clinical evidence. The central issue is not simply whether semaglutide or tirzepatide has been studied. It is whether the exact formulation, service arrangement and follow-up being purchased are adequately described. Sterling provides meaningful details about enrollment, payment and access, alongside unresolved questions about pharmacy identity, final pricing, cancellation and privacy. Its terms also describe a platform intermediary rather than a company directly providing medical care.
At a glance
- Advertised injectable prices
- Semaglutide injection starts at $169 per month; tirzepatide injection starts at $199 per month. Both advertise medication and supplies, with final pricing confirmed after consultation.Sources: [6]
- Microdose offer
- The GLP-1 Microdose program starts at $129 per month with medication and supplies, but the consulted documentation does not specify its active ingredient or route.
- Clinical responsibility
- Sterling’s terms say it does not practice medicine, provide clinical care, prepare or dispense medication, or control independent providers’ and pharmacies’ professional judgment.Sources: [10]
- Recurring billing and cancellation
- Terms authorize an immediate charge and renewal every 30 days. Treatment pages require 30 days’ cancellation notice, while the terms describe disabling auto-refill at least 48 hours before processing.
Start with the product, not the promised result
Sterling describes a private concierge telehealth practice for weight, hormones and healthy aging, serving men and women. GLP-1 programs can be booked online; other services are arranged directly with a physician. The weight-management menu distinguishes semaglutide injection, tirzepatide injection and GLP-1 Microdose. That distinction matters: the first two identify an ingredient and route, while the microdose listing does not provide enough detail to identify the actual preparation being offered.
The semaglutide page says partner compounding pharmacies in the United States prepare medication and ship it on a structured cadence. Sterling’s broader disclosure says practitioners may prescribe customized formulations when commercially available treatments do not meet a patient’s individual needs. It also acknowledges that compounded medications are not FDA approved and that FDA has not independently verified their safety, effectiveness and quality. These disclosures are more informative than treating an ingredient name as a complete product description.
FDA likewise recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, but neither does a shared ingredient name establish equivalence. Our guide to approved medicines and compounded preparations explains these separate questions. Sterling’s documentation does not resolve the precise formulation, quantity per shipment or dispensing-pharmacy identity a particular customer would receive.
Published trials do not validate Sterling’s program
The clinical literature provides evidence about specific studied treatments, not a performance report for Sterling. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks, alongside lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Neither was a trial of Sterling’s service or its compounded preparations.
Both trials also require a tolerability context: gastrointestinal adverse events were important findings, and some participants discontinued treatment because of adverse events. Novo Nordisk funded STEP 1; Eli Lilly funded SURMOUNT-1. Their results do not establish outcomes for other formulations, routes or microdoses, and comparing their headline percentages would not create a randomized head-to-head comparison. The distinction is explained further in why a trial is not a telehealth company performance report.
Sterling’s microdose page targets people near their goal weight, people who tolerated standard GLP-1 treatment poorly and those incorporating treatment into a broader hormone or healthy-aging plan. Those are provider descriptions of intended customers, not demonstrated benefits for the program. The consulted documentation does not establish a product-specific outcome study or comparative tolerability study for Sterling’s microdose offering. Its unspecified ingredient and route make extrapolation from conventional injectable trials especially uncertain.
Who actually provides the care?
Sterling’s marketing emphasizes physician-directed care and an ongoing relationship. Its legal disclosure describes access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies. Those credential descriptions are the company’s claims; the consulted documentation does not identify the individual clinicians, medical groups or pharmacies sufficiently to verify them. A prospective patient therefore has a reasonable basis to request the names of the actual treating and dispensing organizations before relying on the concierge presentation.
The terms draw a sharper organizational boundary: Sterling does not practice medicine, provide clinical care, prepare or dispense medications, or direct the professional judgment of providers and pharmacies. It collects a bundled payment containing separate pharmacy, medical-group and platform portions. This structure does not by itself establish poor care, but it means that the entity taking payment and providing the website is not necessarily the entity responsible for a prescription, a medication question or a dispensing problem.
Enrollment starts with a short online assessment of goals and basic medical history. A licensed clinician reviews that information and, if clinically appropriate, creates a plan and coordinates care. Access requires an account with a username and password. Under the terms, obtaining a prescription also requires a consultation, the provider’s determination that the product is appropriate and an issued prescription. Completing an intake form or paying for access should not be understood as a guaranteed prescription.
What the starting prices actually include
Sterling advertises semaglutide injection from $169 per month, tirzepatide injection from $199 per month and GLP-1 Microdose from $129 per month. Each listing includes medication, supplies, discreet delivery, and concierge care and check-ins. The broader pricing statement includes provider care and says insurance is not required. The semaglutide page additionally says there are no consultation charges or dose-change surcharges. These are advertised inclusions, not evidence that every applicant receives the starting price.
The homepage says final pricing is confirmed after consultation. The documentation does not explain which circumstances increase a quote above the advertised floor, nor does it establish whether laboratory work, other testing or in-person care is included. It also does not specify a separate shipping charge or clearly resolve shipping’s treatment within the final bill. A written quote should distinguish the complete recurring charge from anything obtained outside the bundle.
The billing interval is more specific than the marketing shorthand: recurring orders authorize an immediate charge and another charge every 30 days until cancellation. That is not identical to billing once per calendar month. Sterling says it sends an electronic notification five to seven days before a scheduled transaction and a receipt after a successful charge. The public documentation does not establish introductory-versus-renewal pricing, an annual price lock or a particular medication quantity for each billing interval.
| Offer or term | Documented amount or inclusion | Important qualification |
|---|---|---|
| Semaglutide injection | From $169 per month; medication and supplies | Final price confirmed after consultation |
| Tirzepatide injection | From $199 per month; medication and supplies | Starting price, not a universal quote |
| GLP-1 Microdose | From $129 per month; medication and supplies | Ingredient and route not specified |
| Care bundle | Provider care and concierge support advertised as included | Laboratory and in-person costs not clarified |
| Recurring payment | Immediate charge, then every 30 days | Shipment quantity and exact supply duration not established |
Screening criteria are not an individual eligibility decision
Both the semaglutide and tirzepatide pages describe candidates as adults 18 or older with a BMI of at least 27, or at least 25 with weight-related conditions. These are Sterling’s published criteria, not a statement of universal prescribing standards. NIDDK describes general adult medication thresholds of BMI 30 or higher, or 27 or higher with weight-related health problems. The difference deserves clarification with the treating clinician rather than an assumption that a website threshold establishes suitability.
Sterling’s semaglutide exclusions include a personal or family history of medullary thyroid carcinoma or MEN 2; pregnancy, breastfeeding or planning pregnancy; active pancreatitis; and untreated severe gastrointestinal disease. The site also says its BMI calculator is educational and that a licensed provider determines eligibility. These disclosures outline screening topics, but they do not replace review of medical history, medicines, supplements, allergies and pregnancy plans. NIDDK identifies those discussions as part of medication decision-making.
Geography introduces a separate eligibility limit. Although Sterling advertises national coverage, its terms make availability subject to state-specific rules and possible changes. Users must meet the applicable age-of-majority requirement and be physically located during consultation in the same state as their account’s shipping address. The consulted documentation does not provide an operational state-by-state list or availability by medication. Travel, a different delivery address or a particular state therefore requires confirmation before enrollment.
Pharmacy, packaging and delivery responsibilities
Sterling’s pharmacy arrangement limits choice. Its terms require purchasers of prescription-inclusive services to accept fulfillment through a pharmacy accessible through the platform and waive choosing another pharmacy. The terms say not to purchase if that condition is unacceptable. This is more restrictive than a service that simply sends a prescription to a customer’s preferred pharmacy. Because the consulted documentation does not name the dispensing partners, confirming pharmacy identity is an important unresolved step.
The semaglutide page advertises temperature-controlled, unmarked packaging delivered directly to the home. The terms separately warn that prescription products will not be dispensed in child-resistant containers. Neither discreet packaging nor a temperature-control claim establishes the condition of a particular shipment. FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy to resolve the concern.
No reliable clinical-review, pharmacy-preparation, dispatch or arrival timeline is established in the consulted documentation. The phrase “structured cadence” does not disclose shipment quantity or exact supply duration, and dispatch would not establish arrival. Our guide to reading cold-chain and delivery claims explains why those distinctions matter. Before paying, a customer can reasonably ask who handles delivery problems, how the pharmacy can be reached and what procedure applies to a temperature-compromised shipment.
Follow-up promises need a clinical timetable
Sterling advertises structured check-ins intended to adjust the protocol and broader plan to a patient’s response. It also offers around-the-clock messaging through a private patient portal. These are relevant service features, but the documentation does not specify the interval between clinical reviews, who answers each type of message or how quickly a prescribing clinician responds. Continuous access to a messaging channel is not the same as continuous clinician availability.
The contact page lists support@sterlingprivatemedical.com, telephone (475) 290-6731 and secure messaging available 24/7. It separately promises a response within 24 hours to messages sent through its contact form. That response target should not be read as a prescription-review deadline or shipping promise. The consulted documentation also does not establish Spanish-language care, interpretation or multilingual clinical materials, which may be important practical questions for some households.
NIDDK describes follow-up as an assessment of response and tolerability, not merely continued payment, and notes that treatment duration depends on benefits and side effects. Sterling’s public check-in promise is consistent with the need for follow-up but does not demonstrate its quality or outcomes. The useful next question is operational: what review occurs before renewal, what information is collected and which clinician acts on it? Our guide to clinical follow-up versus renewal notices develops that distinction.
Cancellation and privacy disclosures do not fully align
Two cancellation instructions appear in Sterling’s documentation. Treatment pages say memberships may be canceled with 30 days’ notice before the next billing cycle. The terms instead describe turning off auto-refill in the portal at least 48 hours before monthly processing. This review cannot resolve which instruction controls a particular purchase. Given the immediate charge and recurring 30-day billing authorization, written confirmation of the applicable deadline is more useful than assuming the shorter window always applies.
Cancellation also does not imply a refund. Treatment pages state that consultations, medical visits and fulfilled prescriptions become nonrefundable once services begin or medication is processed. Separately, privacy language needs careful reading: the semaglutide page says medical information is shared only with the physician and dispensing pharmacy and makes a broad promise not to sell or share data. The California notice says certain advertising-related personal-information disclosures may count as a sale or sharing under California law.
These privacy statements concern potentially different information categories, so they should not be collapsed into a finding that medical records are sold. They do, however, make the broad marketing assurance incomplete without the detailed notice. The terms also say Sterling is not a HIPAA covered entity and may act as a business associate in some circumstances. Part of the consulted terms was unavailable, and a separate HIPAA notice was not consulted; no comprehensive privacy or legal conclusion is possible.
Questions & answers
Is Sterling itself the medical practice prescribing my medication?
Its marketing uses practice-oriented language, but the terms say Sterling does not provide clinical care. Independent providers determine whether to prescribe, and separate pharmacies fulfill prescriptions. Ask for the treating clinician’s name, medical-group identity and dispensing pharmacy rather than assuming all three roles belong to Sterling.
Will I definitely pay the advertised starting price?
No universal price is established. The advertised floors are $169 monthly for semaglutide injection, $199 for tirzepatide injection and $129 for GLP-1 Microdose. Sterling says final pricing is confirmed after consultation. Request the complete quote, recurring 30-day charge, supplied quantity and any outside testing costs before authorizing payment.
Does Sterling’s microdose program have the same evidence as standard injectable treatment?
That is not established. Sterling describes intended users, but the consulted documentation does not identify the microdose ingredient or route or establish a program-specific outcome study. STEP 1 and SURMOUNT-1 do not validate Sterling’s microdose protocol, its tolerability claims or results for an individual customer.
Can I use my usual pharmacy?
Not under the documented prescription-inclusive purchase terms. They require accepting fulfillment through a platform-accessible pharmacy and waiving selection of another pharmacy. The consulted documentation does not name the dispensing partners. Confirm the pharmacy, its contact details and the preparation being prescribed before deciding whether that restriction is acceptable.
How much notice does Sterling require to cancel?
The public documents differ: treatment pages require 30 days before the next billing cycle, while the terms describe disabling portal auto-refill at least 48 hours before processing. Obtain written clarification and retain the cancellation confirmation. Stopping future renewal does not establish a refund for services begun or medication processed.
Does 24/7 messaging mean an immediate medical answer?
No immediate clinician-response commitment is documented. Sterling advertises around-the-clock portal messaging and separately promises a contact-form response within 24 hours. Ask who monitors clinical questions and when a prescriber responds. For injectable medication arriving warm or inadequately refrigerated, FDA advises not using it and contacting the provider or pharmacy.
Our assessment
Sterling documents a recognizable compounded-GLP-1 service: online assessment, independent prescribing, bundled recurring payments, pharmacy fulfillment, home delivery and advertised follow-up. Its starting prices and acknowledgement of compounded drugs’ nonapproved status provide useful information. The evidence is substantially weaker for product-specific effectiveness, microdose benefits and the quality or speed of clinical support. Published drug trials cannot fill those gaps. Before enrollment, the most useful documentary requests are a final itemized quote, exact formulation and supply quantity, clinician and pharmacy identities, state availability, a clinical follow-up schedule and one unambiguous cancellation rule. Privacy representations also warrant reading beyond the treatment-page assurance. Sterling’s documentation supports describing an available commercial program, not endorsing its outcomes or treating its concierge presentation as independent evidence of clinical quality.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Sterling Private Medical — treatments/semaglutide ↗
- Sterling Private Medical — official website ↗
- Sterling Private Medical — about ↗
- Sterling Private Medical — contact ↗
- Sterling Private Medical — privacy ↗
- Sterling Private Medical — terms ↗
- Sterling Private Medical — treatments/tirzepatide ↗
- Sterling Private Medical — treatments/glp 1 microdose ↗